Therapy of uncomplicated malaria in children: A review of treatment principles, essential drugs and current recommendations

Tropical Medicine and International Health

Volumn 13, Issue 9, 2008, Pages 1111-1130

  Deen, Jacqueline L ^a,b   Von Seidlein, Lorenz ^a,c,d   Dondorp, Arjen ^d  

^a Joint Malaria Programme   (Tanzania)

^b International Vaccine Institute   (South Korea)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

Author keywords

Amodiaquine; Artemisinin combination therapies; Chloroquine; Malaria; Mefloquine; Ovale and malariae; Plasmodium falciparum; Primaquine; Quinine; Sulfadoxine pyrimethamine; Vivax

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CLINDAMYCIN; DAPSONE; DIAZEPAM; DIHYDROARTEMISININ; DOXYCYCLINE; FANSIDAR; HALOFANTRINE; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; QUININE; SULFADOXINE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHILD HEALTH; DISEASE TREATMENT; DRUG; MALARIA; PROTOZOAN; QUININE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABNORMAL DREAMING; ACIDOSIS; AGRANULOCYTOSIS; AMINOACIDURIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIMALARIAL ACTIVITY; APLASTIC ANEMIA; AREA UNDER THE CURVE; ASEPTIC MENINGITIS; ASTHMA; ATAXIA; BACTERIAL INFECTION; BALANCE IMPAIRMENT; BLACK WATER FEVER; BLOOD DISEASE; BRADYCARDIA; BRAIN DISEASE; BRONCHOSPASM; CANDIDIASIS; CHEMOPROPHYLAXIS; CHRONIC DRUG ADMINISTRATION; CINCHONISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONVULSION; COST EFFECTIVENESS ANALYSIS; CRYSTALLURIA; CYTOPENIA; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG RAASH; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPHAGIA; DYSPHORIA; ECG ABNORMALITY; ENAMEL HYPOPLASIA; EOSINOPHILIA; ERYTHEMA NODOSUM; ESOPHAGUS ULCER; EXFOLIATIVE DERMATITIS; EYE DISEASE; FATIGUE; FIBROSING ALVEOLITIS; FLUSHING; GASTROINTESTINAL SYMPTOM; GLOSSITIS; GLUCOSURIA; HAIR LOSS; HEARING; HEART ARREST; HEART PALPITATION; HEMATOPOIESIS; HEMATURIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEPATITIS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERURICEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOPROTHROMBINEMIA; HYPOTENSION; INFECTION PREVENTION; INJECTION SITE NECROSIS; INJECTION SITE PAIN; INSOMNIA; INTERSTITIAL NEPHRITIS; INTRACRANIAL PRESSURE; JAUNDICE; KERATOPATHY; KIDNEY FAILURE; LEUKOCYTOSIS; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LOEFFLER PNEUMONIA; MALARIA; MALARIA FALCIPARUM; MEGALOBLASTIC ANEMIA; MENTAL DISEASE; METHEMOGLOBINEMIA; MONOTHERAPY; MULTIDRUG RESISTANCE; MUSCLE WEAKNESS; MYOCARDITIS; MYOPATHY; NAUSEA; NERVE PARALYSIS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OLIGURIA; ORTHOSTATIC HYPOTENSION; OTOTOXICITY; PALATABILITY; PANCREATITIS; PANCYTOPENIA; PARASITEMIA; PEDIATRICS; PERICARDITIS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; POLYARTERITIS NODOSA; POLYDIPSIA; POLYURIA; PRACTICE GUIDELINE; PROTEINURIA; PRURITUS; PSEUDOMEMBRANOUS COLITIS; PSYCHOSIS; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; RETICULOCYTOPENIA; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SCIATIC NEUROPATHY; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; TACHYCARDIA; THROMBOCYTOPENIA; TINNITUS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; URTICARIA; VERTIGO; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA; MALE; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM;

EID: 50049120658     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2008.02117.x     Document Type: Review

References (151)

1. Adjuik M, Agnamey P, Babiker A et al. (2002) Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359, 1365 1372.
2. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W White N (2004) Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363, 9 17.
3. Alker AP, Mwapasa V, Purfield A et al. (2005) Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrobial Agents and Chemotherapy 49, 3919 3921.
4. Alker AP, Lim P, Sem R et al. (2007) Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. The American Journal of Tropical Medicine and Hygiene 76, 641 647.
5. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM White NJ (2006) Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clinical Pharmacology and Therapeutics 80, 582 596.
6. Batty KT, Thu LT, Davis TM et al. (1998) A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. British Journal of Clinical Pharmacology 45, 123 129.
7. Bejon P, Berkley JA, Mwangi T et al. (2007) Defining childhood severe falciparum malaria for intervention studies. PLoS Medicine 4, e251.
8. Bell DJ, Nyirongo SK, Mukaka M et al. (2008) Sulfadoxine-pyrimethamine- based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS ONE 3, e1578.
9. Bem JL, Kerr L Stuerchler D (1992) Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. The Journal of Tropical Medicine and Hygiene 95, 167 179.
10. Bethell DB, Teja-Isavadharm P, Cao XT et al. (1997) Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 91, 195 198.
11. Bjorkman A Phillips-Howard PA (1991) Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bulletin of the World Health Organization 69, 297 304.
12. Boland ME, Roper SM Henry JA (1985) Complications of quinine poisoning. Lancet 1, 384 385.
13. Brasseur P, Agnamey P, Gaye O, Vaillant M, Taylor WR Olliaro PL (2007) Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Senegal. Malaria Journal 6, 150.
14. Bray PG, Mungthin M, Ridley RG Ward SA (1998) Access to hematin: the basis of chloroquine resistance. Molecular Pharmacology, 54, 170 179.
15. Brewer TG, Peggins JO, Grate SJ et al. (1994) Neurotoxicity in animals due to arteether and artemether. Transactions of the Royal Society of Tropical Medicine and Hygiene 88 Suppl 1, S33 S36.
16. Bruce-Chwatt LJ (1987) Quinine and the mystery of blackwater fever. Acta Leidensia 55, 181 196.
17. Chan TK, Todd D Tso SC (1976) Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. British Medical Journal 2, 1227 1229.
18. Clemessy JL, Angel G, Borron SW et al. (1996a) Therapeutic trial of diazepam versus placebo in acute chloroquine intoxications of moderate gravity. Intensive Care Medicine, 22, 1400 1405.
19. Clemessy JL, Taboulet P, Hoffman JR et al. (1996b) Treatment of acute chloroquine poisoning: a 5-year experience. Critical Care Medicine 24, 1189 1195.
20. Collins WE Jeffery GM (1996) Primaquine resistance in Plasmodium vivax. The American Journal of Tropical Medicine and Hygiene 55, 243 249.
21. Cowman AF, Galatis D Thompson JK (1994) Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proceedings of the National Academy of Sciences of the United States of America 91, 1143 1147.
22. Cox-Singh J, Davis TM, Lee KS et al. (2008) Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clinical Infectious Diseases 46, 165 171.
23. Denis MB, Tsuyuoka R, Poravuth Y et al. (2006) Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Tropical Medicine & International Health 11, 1360 1366.
24. Dondorp A, Nosten F, Stepniewska K, Day N White N (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366, 717 725.
25. Dorsey G, Njama D, Kamya MR et al. (2002) Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 360, 2031 2038.
26. Durand R, Prendki V, Cailhol J et al. (2008) Plasmodium falciparum malaria and atovaquone-proguanil treatment failure. Emerging Infectious Diseases 14, 320 322.
27. Eckstein-Ludwig U, Webb RJ, Van Goethem ID et al. (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424, 957 961.
28. Ezzet F, Mull R Karbwang J (1998) Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. British Journal of Clinical Pharmacology 46, 553 561.
29. Ezzet F, van Vugt M, Nosten F, Looareesuwan S White NJ (2000) Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrobial Agents and Chemotherapy 44, 697 704.
30. Fanello CI, Karema C, Ngamije D et al. (2008) A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 102, 412 20.
31. Field J Edeson J (1949) Paludrine resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 43, 233 236.
32. Field JW, Strahan JH, Edeson JF Wilson T (1954) Studies on the chemotherapy of malaria. II. The treatment of acute malaria with proguanil (paludrine). Medical Journal of Malaya 8, 303 317.
33. Foote SJ Cowman AF (1994) The mode of action and the mechanism of resistance to antimalarial drugs. Acta tropica 56, 157 171.
34. Gasasira AF, Kamya MR, Achan J et al. (2008) High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clinical Infectious Diseases 46, 985 991.
35. Grande T, Bernasconi A, Erhart A et al. (2007) A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS ONE 2, e1101.
36. Hall AP, Czerwinski AW, Madonia EC Evensen KL (1973) Human plasma and urine quinine levels following tablets, capsules, and intravenous infusion. Clinical Pharmacology and Therapeutics 14, 580 585.
37. Hatton CS, Peto TE, Bunch C et al. (1986) Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1, 411 414.
38. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K Sibley CH (2007) Antifolates can have a role in the treatment of Plasmodium vivax. Trends in Parasitology 23, 213 222.
39. van Hensbroek MB, Kwiatkowski D, van den Berg B, Hoek FJ, van Boxtel CJ Kager PA (1996) Quinine pharmacokinetics in young children with severe malaria. American Journal of Tropical Medicine and Hygiene 54, 237 242.
40. Hien TT, Turner GD, Mai NT et al. (2003) Neuropathological assessment of artemether-treated severe malaria. Lancet 362, 295 296.
41. Hien TT, Davis TM, Chuong LV et al. (2004) Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrobial Agents and Chemotherapy 48, 4234 4239.
42. Ilett KF, Batty KT, Powell SM et al. (2002) The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. British Journal of Clinical Pharmacology 53, 23 30.
43. Jambou R, Legrand E, Niang M et al. (2005) Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366, 1960 1963.
44. Karbwang J, Bangchang KN, Bunnag D Harinasuta T (1991) Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. Bulletin of the World Health Organization 69, 207 212.
45. Kennedy AF (1955) Absolute neutrophil leucopenia after uncontrolled use of amodiaquine. British Medical Journal 2, 475 476.
46. Kissinger E, Hien TT, Hung NT et al. (2000) Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. American Journal of Tropical Medicine and Hygiene 63, 48 55.
47. Krishna S White NJ (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clinical Pharmacokinetics 30, 263 299.
48. Krishna S, Planche T, Agbenyega T et al. (2001) Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrobial Agents and Chemotherapy 45, 509 516.
49. Krugliak M Ginsburg H (1991) Studies on the antimalarial mode of action of quinoline-containing drugs: time-dependence and irreversibility of drug action, and interactions with compounds that alter the function of the parasite's food vacuole. Life Sciences 49, 1213 1219.
50. ter Kuile FO, Nosten F, Luxemburger C et al. (1995) Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bulletin of the World Health Organization 73, 631 642.
51. Laufer MK, Thesing PC, Eddington ND et al. (2006) Return of chloroquine antimalarial efficacy in Malawi. New England Journal of Medicine 355, 1959 1966.
52. Lemnge M, Alifrangis M, Kafuye MY et al. (2006) High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania. American Journal of Tropical Medicine and Hygiene 75, 188 193.
53. Leonardi E, Gilvary G, White NJ Nosten F (2001) Severe allergic reactions to oral artesunate: a report of two cases. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 182 183.
54. Leslie T, Mayan MI, Hasan MA et al. (2007) Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. Journal of American Medical Association 297, 2201 2209.
55. Li Q, Xie LH, Haeberle A, Zhang J Weina P (2006) The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans. American Journal of Tropical Medicine and Hygiene 75, 817 826.
56. Looareesuwan S, Harinasuta T Chongsuphajaisiddhi T (1992a) Drug resistant malaria, with special reference to Thailand. Southeast Asian Journal of Tropical Medicine and Public Health 23, 621 634.
57. Looareesuwan S, Wilairatana P, Vanijanonta S, Kyle D Webster K (1992b) Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet 339, 369.
58. Maguire JD, Sumawinata IW, Masbar S et al. (2002) Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 360, 58 60.
59. Mandi G, Mockenhaupt FP, Coulibaly B, Meissner P Muller O (2008) Efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of rural north-western Burkina Faso. Malaria Journal 7, 58.
60. Mansor SM, Molyneux ME, Taylor TE, Ward SA, Wirima JJ Edwards G (1991) Effect of Plasmodium falciparum malaria infection on the plasma concentration of alpha 1-acid glycoprotein and the binding of quinine in Malawian children. British Journal of Clinical Pharmacology 32, 317 321.
61. Massaga JJ, Kitua AY, Lemnge MM et al. (2003) Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet, 361, 1853 1860.
62. Meek SR, Doberstyn EB, Gauzere BA, Thanapanich C, Nordlander E Phuphaisan S (1986) Treatment of falciparum malaria with quinne and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai-Kampuchean border. American Journal of Tropical Medicine and Hygiene 35, 246 250.
63. Mihaly GW, Ward SA, Edwards G, Orme ML Breckenridge AM (1984) Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. British Journal of Clinical Pharmacology 17, 441 446.
64. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML Breckenridge AM (1985) Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. British Journal of Clinical Pharmacology 19, 745 750.
65. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R Campbell CC (1986) Severe cutaneous reactions among American travelers using pyrimethamine- sulfadoxine (Fansidar) for malaria prophylaxis. American Journal of Tropical Medicine and Hygiene 35, 451 458.
66. Mithwani S, Aarons L, Kokwaro GO et al. (2004) Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. British Journal of Clinical Pharmacology 57, 146 152.
67. Mnyika KS Kihamia CM (1991) Chloroquine-induced pruritus: its impact on chloroquine utilization in malaria control in Dar es Salaam. Journal of Tropical Medicine and Hygiene 94, 27 31.
68. Mueller EA, van Vugt M, Kirch W, Andriano K, Hunt P de Palacios PI (2006) Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Tropica 100, 41 53.
69. Murphy SA, Mberu E, Muhia D et al. (1997) The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Transactions of the Royal Society of Tropical Medicine and Hygiene 91, 331 334.
70. Mwangi TW, Ross A, Snow RW Marsh K (2005) Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. Journal of Infectious Diseases 191, 1932 1939.
71. Nakato H, Vivancos R Hunter PR (2007) A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. Journal of Antimicrobial Chemotherapy 60, 929 936.
72. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q Olliaro P (2000) Pharmacokinetics of artemisinin-type compounds. Clinical Pharmacokinetics 39, 255 270.
73. Ndayiragije A, Niyungeko D, Karenzo J et al. (2004) Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi. Tropical Medicine & International Health 9, 673 679.
74. Newton P, Keeratithakul D, Teja-Isavadharm P, Pukrittayakamee S, Kyle D White N (1999) Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. Transactions of the Royal Society of Tropical Medicine and Hygiene 93, 69 72.
75. Newton P, Suputtamongkol Y, Teja-Isavadharm P et al. (2000) Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrobial Agents and Chemotherapy 44, 972 977.
76. Newton PN, Chaulet JF, Brockman A et al. (2005) Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. Antimicrobial Agents and Chemotherapy 49, 1622 1625.
77. Nguyen TH, Day NP, Ly VC et al. (1996) Post-malaria neurological syndrome. Lancet 348, 917 921.
78. Nontprasert A, Pukrittayakamee S, Dondorp AM, Clemens R, Looareesuwan S White NJ (2002) Neuropathologic toxicity of artemisinin derivatives in a mouse model. American Journal of Tropical Medicine and Hygiene 67, 423 429.
79. Nosten F, ter Kuile F, Chongsuphajaisiddhi T et al. (1991a) Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 337, 1140 1143.
80. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Na Bangchang K, Karbwang J White NJ (1991b) Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. British Journal of Clinical Pharmacology, 31, 556 559.
81. Nsimba B, Guiyedi V, Mabika-Mamfoumbi M et al. (2008) Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy. Malaria Journal 7, 31.
82. Oduola AM, Sowunmi A, Milhous WK et al. (1992) Innate resistance to new antimalarial drugs in Plasmodium falciparum from Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene 86, 123 126.
83. Okiro EA, Hay SI, Gikandi PW et al. (2007) The decline in paediatric malaria admissions on the coast of Kenya. Malaria Journal 6, 151.
84. Olliaro P, Nevill C, LeBras J et al. (1996) Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348, 1196 2001.
85. Omari AA, Gamble C Garner P (2004) Artemether-lumefantrine for treating uncomplicated falciparum malaria. In : The Cochrane Library. John Wiley & Sons, Chichester.
86. Omari AA, Gamble C Garner P (2005) Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane database of systematic reviews (Online), CD005564.
87. Omari AA, Gamble C Garner P (2006) Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane database of systematic reviews (Online), CD005965.
88. Orrell C, Little F, Smith P et al. (2008) Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. European Journal of Clinical Pharmacology 64, 683 690.
89. Osei-Akoto A, Orton L Owusu-Ofori SP (2005) Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 4, CD004529.
90. Peters W (1987) Chemotherapy and drug resistance in malaria parasites Academic Press, London.
91. Peterson DS, Milhous WK Wellems TE (1990) Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proceedings of the National Academy of Sciences of the United States of America, 87, 3018 3022.
92. Phillips RE, Looareesuwan S, White NJ, Silamut K, Kietinun S Warrell DA (1986) Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. British Journal of Clinical Pharmacology 21, 677 683.
93. Phillips-Howard PA ter Kuile FO (1995) CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Safety 12, 370 383.
94. Price R, Simpson JA, Teja-Isavatharm P et al. (1999a) Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrobial Agents and Chemotherapy 43, 341 346.
95. Price R, van Vugt M, Phaipun L et al. (1999b) Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. American Journal of Tropical Medicine and Hygiene 60, 547 555.
96. Price RN, Cassar C, Brockman A et al. (1999c) The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrobial Agents and Chemotherapy, 43, 2943 2949.
97. Price RN, Uhlemann AC, van Vugt M et al. (2006) Molecular and pharmacological determinants of the therapeutic response to artemether- lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clinical Infectious Diseases 42, 1570 1577.
98. Pukrittayakamee S, Supanaranond W, Looareesuwan S, Vanijanonta S White NJ (1994) Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene 88, 324 327.
99. Pukrittayakamee S, Looareesuwan S, Keeratithakul D et al. (1997) A study of the factors affecting the metabolic clearance of quinine in malaria. European Journal of Clinical Pharmacology 52, 487 493.
100. Pukrittayakamee S, Chantra A, Simpson JA et al. (2000a) Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrobial Agents and Chemotherapy 44, 1680 1685.
101. Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S White NJ (2000b) Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrobial Agents and Chemotherapy 44, 2395 2398.
102. Pukrittayakamee S, Prakongpan S, Wanwimolruk S et al. (2003) Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. Antimicrobial Agents and Chemotherapy 47, 1509 1513.
103. Pussard E, Lepers JP, Clavier F et al. (1991) Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria. Antimicrobial Agents and Chemotherapy, 35, 406 409.
104. Ratcliff A, Siswantoro H, Kenangalem E et al. (2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369, 757 765.
105. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B Cowman AF (1996) Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. American Journal of Tropical Medicine and Hygiene 55, 209 213.
106. Reyes P, Rathod PK, Sanchez DJ, Mrema JE, Rieckmann KH Heidrich HG (1982) Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Molecular and Biochemical Parasitology 5, 275 290.
107. Ribeiro IR Olliaro P (1998) Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Medecine tropicale 58, 50 53.
108. Riou B, Barriot P, Rimailho A Baud FJ (1988) Treatment of severe chloroquine poisoning. New England Journal of Medicine, 318, 1 6.
109. Rose GW, Suh KN, Kain KC, Le Saux N McCarthy AE (2008) Atovaquone-Proguanil Resistance in Imported Falciparum Malaria in a Young Child. Pediatric Infectious Disease Journal 27, 567 569.
110. Savini H, Bogreau H, Bertaux L et al. (2008) First Case of Emergence of Atovaquone-Proguanil (MalaroneTM) Resistance in Plasmodium falciparum During Treatment in Traveller from Comoros. Antimicrobial Agents and Chemotherapy 52, 2283 2284.
111. Schellenberg JR, Smith T, Alonso PL Hayes RJ (1994) What is clinical malaria? Finding case definitions for field research in highly endemic areas Parasitology Today 10, 439 442.
112. Silamut K, White NJ, Looareesuwan S Warrell DA (1985) Binding of quinine to plasma proteins in falciparum malaria. American Journal of Tropical Medicine and Hygiene 34, 681 686.
113. Silamut K, Molunto P, Ho M, Davis TM White NJ (1991) Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. British Journal of Clinical Pharmacology 32, 311 315.
114. Simpson JA, Price R, ter Kuile F et al. (1999) Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clinical Pharmacology and Therapeutics 66, 472 484.
115. Singh B, Kim Sung L, Matusop A et al. (2004) A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 363, 1017 1024.
116. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y Santi DV (1997) Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proceedings of the National Academy of Sciences of the United States of America 94, 1124 1129.
117. Slutsker LM, Khoromana CO, Payne D et al. (1990) Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bulletin of the World Health Organization 68, 53 59.
118. Smith T, Schellenberg JA Hayes R (1994) Attributable fraction estimates and case definitions for malaria in endemic areas. Statistics in Medicine 13, 2345 2358.
119. Sowunmi A (1996) Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. East African Medical Journal 73, 519 523.
120. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F Vaidya AB (1999) Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. MolecularMicrobiology 33, 704 711.
121. Supanaranond W, Davis TM, Pukrittayakamee S et al. (1991) Disposition of oral quinine in acute falciparum malaria. European Journal of Clinical Pharmacology 40, 49 52.
122. Taylor WR White NJ (2004) Antimalarial drug toxicity: a review. Drug safety 27, 25 61.
123. Taylor WR, Terlouw DJ, Olliaro PL, White NJ, Brasseur P ter Kuile FO (2006) Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bulletin of the World Health Organization 84, 956 964.
124. Tran TH, Dolecek C, Pham PM et al. (2004) Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363, 18 22.
125. Trape JF, Pison G, Preziosi MP et al. (1998) Impact of chloroquine resistance on malaria mortality. Comptes rendus de 71' Academie des sciences 321, 689 697.
126. Van Vugt M, Angus BJ, Price RN et al. (2000) A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 62, 65 69.
127. Verdrager J (1986) Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. Journal of Tropical Medicine and Hygiene 89, 277 289.
128. Verdrager J (1995) Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Southeast Asian Journal of Tropical Medicine and Public Health 26, 23 28.
129. van Vugt M, Brockman A, Gemperli B et al. (1998) Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrobial Agents and Chemotherapy 42, 135 139.
130. van Vugt M, Ezzet F, Nosten F et al. (1999) No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. American Journal of Tropical Medicine and Hygiene 61, 964 967.
131. Ward SA, Mihaly GW, Edwards G et al. (1985) Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. British Journal of Clinical Ppharmacology 19, 751 755.
132. Watkins WM, Woodrow C Marsh K (1993) Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy. American Journal of Tropical Medicine and Hygiene 49, 106 112.
133. Watt G, Loesuttivibool L, Shanks GD et al. (1992) Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand. American Journal of Tropical Medicine and Hygiene 47, 108 111.
134. Wernsdorfer WH (1994) Epidemiology of drug resistance in malaria. Acta Tropica 56, 143 156.
135. White NJ (1992) Antimalarial drug resistance: the pace quickens. Journal of Antimicrobial Chemotherapy, 30, 571 585.
136. White NJ (1996) The treatment of malaria. New England Journal of Mmedicine 335, 800 806.
137. White N (1999) Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society of London 354, 739 749.
138. White NJ (2007) Cardiotoxicity of antimalarial drugs. Lancet Infectious Diseases 7, 549 558.
139. White N (2008) Qinghaosu (Artemisinin): The Price of Success. Science 320, 330 334.
140. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D Harinasuta T (1982) Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. American Journal of Medicine 73, 564 572.
141. White NJ, Looareesuwan S Warrell DA (1983) Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. Journal of Cardiovascular Pharmacology 5, 173 175.
142. White NJ, van Vugt M Ezzet F (1999) Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clinical Pharmacokinetics 37, 105 125.
143. WHO (1999) IMCI Information Package WHO/CHS/CAH/98.1) WHO, Geneva.
144. WHO (2005) Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Illnesses with Limited Resources. WHO, Geneva.
145. WHO (2006) Guidelines for the Treatment of Malaria. WHO/HTM/MAL/2006. 1108. WHO, Geneva.
146. WHO (2008) Development of Paediatric Medicines: Pharmaceutical Development. Points to consider Working document QAS/08.257. WHO, Geneva.
147. Wilson CM, Volkman SK, Thaithong S et al. (1993) Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Molecular and Biochemical Parasitology 57, 151 160.
148. Winstanley PA, Watkins WM, Newton CR et al. (1992) The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. British Journal of Clinical Pharmacology 33, 143 148.
149. Wongsrichanalai C Meshnick SR (2008) Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia-Thailand Border. Emerging Infectious Diseases 14, 716 719.
150. Yang H, Liu D, Yang Y et al. (2003) Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. Transactions of the Royal Society of Tropical Medicine and Hygiene 97, 226 228.
151. Yeka A, Banek K, Bakyaita N et al. (2005) Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Medicine 2, e190.